|Contact:||wdenney at humanpredictions.com|
|Contributions:||Suggestions and improvements for this task view are very welcome and can be made through issues or pull requests on GitHub or via e-mail to the maintainer address. For further details see the Contributing guide.|
|Citation:||Bill Denney (2022). CRAN Task View: Analysis of Pharmacokinetic Data. Version 2022-12-05. URL https://CRAN.R-project.org/view=Pharmacokinetics.|
|Installation:||The packages from this task view can be installed automatically using the ctv package. For example, |
Analysis of pharmacokinetic (PK) data is concerned with defining the relationship between the dosing regimen and the body’s exposure to drug as indicated by the concentration time curve to determine a dose. To analyze PK data, there are three categories of packages within CRAN: noncompartmental analysis (NCA), modeling (typically using compartmental analysis), and reporting (typically for NCA).
Pharmacokinetics are often collected during clinical trials of new drugs. For more information on R packages for clinical trials, see ClinicalTrials.
CRAN task views hopes that all task views will have multiple maintainers from diverse backgrounds. If you are interested in becoming a co-maintainer of this task view, please contact the current maintainer (listed at the top of the task view).
NCA is used as method of description of PK with minimal assumptions of the rates of distribution of the drug through the body. NCA is typically used to describe the PK of a drug in clinical studies with many samples per subject on the same and sequential days.
The NCA packages are:
ncappc: Performs traditional NCA and simulation-based posterior predictive checks for a population PK model using NCA metrics. It targets summarizing data from model-fit or simulated sources.
NonCompart: Provides basic computational functions for NCA.
PK: Allows estimation of pharmacokinetic parameters using non-compartmental theory. Both complete sampling and sparse sampling designs are implemented. The package provides methods for hypothesis testing and confidence intervals related to superiority and equivalence.
PKNCA: Computes standard NCA parameters and summarizes them with the goal of taking in observed clinical data and providing summaries ready for study reports and regulatory submission.
qpNCA: Noncompartmental Pharmacokinetic Analysis by qPharmetra
Modeling of PK data typically uses compartmental methods which assume that the drug enters the body either through an intravenous (IV) or extravascular (often oral or subcutaneous, SC) dose. Packages listed below are restricted to packages that have specific interest to PK modeling and not the (many) packages that support modeling that could be used for PK data. The PK modeling and simulation packages are:
bayesnec: A Bayesian No-Effect- Concentration (NEC) Algorithm
clinPK: Calculates equations commonly used in clinical pharmacokinetics and clinical pharmacology, such as equations for dose individualization, compartmental pharmacokinetics, drug exposure, anthropomorphic calculations, clinical chemistry, and conversion of common clinical parameters. Where possible and relevant, it provides multiple published and peer-reviewed equations within the respective R function.
cpk: Provides simplified clinical pharmacokinetic functions for dose regimen design and modification at the point-of-care.
clinDR: Bayesian and ML Emax model fitting, graphics and simulation for clinical dose response.
clustDRM: Functions to identify the pattern of a dose-response curve. Then fit a set of appropriate models to it according to the identified pattern, followed by model averaging to estimate the effective dose.
dfpk: Provides statistical methods involving PK measures for dose finding in Phase 1 clinical trials.
dr4pl: Dose Response Data Analysis using the 4 Parameter Logistic (4pl) Model
linpk: Generate Concentration-Time Profiles from Linear PK Systems
mrgsolve: Facilitates simulation from hierarchical, ordinary differential equation (ODE) based models typically employed in drug development.
nonmemica: Systematically creates and modifies NONMEM(R) control streams. Harvests NONMEM output, builds run logs, creates derivative data, generates diagnostics.
rxode2: Methods for simulation from drug development hierarchical ordinary differential equations (ODE). This is the basis of the nlmixr2 package and supersedes the
nlmixr2: Nonlinear Mixed Effects Models in Population PK/PD (superseding the
nmw: Is a package to understand the algorithms of NONMEM.
PKconverter: The Parameter Converter of the Pharmacokinetic Models
pkdata: Creates Pharmacokinetic/Pharmacodynamic (PK/PD) Data
pmxTools: Pharmacometric tools for common data analytical tasks; closed-form solutions for calculating concentrations at given times after dosing based on compartmental PK models (1-compartment, 2-compartment and 3-compartment, covering infusions, zero- and first-order absorption, and lag times, after single doses and at steady state, per Bertrand & Mentre (2008)); parametric simulation from NONMEM-generated parameter estimates and other output; and parsing, tabulating and plotting results generated by Perl-speaks-NONMEM (PsN).
ubiquity: PKPD, PBPK, and Systems Pharmacology Modeling Tools
UnifiedDoseFinding: Dose-Finding Methods for Non-Binary Outcomes
wnl: Minimization Tool for Pharmacokinetic-Pharmacodynamic Data Analysis
nlmeVPC: Various visual and numerical diagnosis methods for the nonlinear mixed effect model, including visual predictive checks, numerical predictive checks, and coverage plots.
xpose4: A model building aid for nonlinear mixed-effects (population) model analysis using NONMEM, facilitating data set checkout, exploration and visualization, model diagnostics, candidate covariate identification and model comparison.
Communication of results is as important (or more important) than actually completing an analysis. While many users are currently using rmarkdown and knitr for general reporting, the features of packages which are important for reporting PK data are:
ncar: Provides NCA for a report writer generating rtf and pdf output.
pkr: Generates NCA data sets compliant to CDISC and other pharmacokinetic functions for reviewer.
xpose: Diagnostics for non-linear mixed-effects (population) models from ‘NONMEM’. ‘xpose’ facilitates data import, creation of numerical run summary and provide ‘ggplot2’-based graphics for data exploration and model diagnostics.
xpose.nlmixr2: Graphical Diagnostics for Pharmacometric Models: Extension to ‘nlmixr2’ (superseding the
nlmixr2rpt: Provides automatic reporting of
nlmixr2 models as word documents and powerpoint documents.
Packages that focus on a single pharmacokinetic model or dataset include:
caffsim: Simulate plasma caffeine concentrations using population pharmacokinetic model described in Lee, Kim, Perera, McLachlan and Bae (2015)
Packages related to PK study design include:
BE: Analyze bioequivalence study data with industrial strength. Sample size could be determined for various crossover designs, such as 2x2 design, 2x4 design, 4x4 design, Balaam design, Two-sequence dual design, and William design.
dfpk: Statistical methods involving PK measures are provided, in the dose allocation process during a Phase I clinical trials. These methods, proposed by Ursino et al, (2017) doi:10.1002/bimj.201600084, enter pharmacokinetics (PK) in the dose finding designs in different ways, including covariates models, dependent variable or hierarchical models. This package provides functions to generate data from several scenarios and functions to run simulations which their objective is to determine the maximum tolerated dose (MTD).
microsamplingDesign: Find optimal microsampling designs for non-compartmental pharacokinetic analysis using a general simulation methodology. This methodology consist of (1) specifying a pharmacokinetic model including variability among animals; (2) generating possible sampling times; (3) evaluating performance of each time point choice on simulated data; (4) generating possible schemes given a time point choice and additional constraints and finally (5) evaluating scheme performance on simulated data. The default settings differ from the article of Barnett and others, in the default pharmacokinetic model used and the parameterization of variability among animals.
PopED: computes optimal experimental designs for both population and individual studies based on nonlinear mixed-effect models.
|Regular:||bayesnec, BE, caffsim, clinDR, clinPK, clustDRM, cpk, dfpk, dr4pl, linpk, microsamplingDesign, mrgsolve, ncappc, ncar, nlmeVPC, nlmixr2, nlmixr2rpt, nmw, NonCompart, nonmemica, PK, PKconverter, pkdata, PKNCA, pkr, pmxTools, PopED, qpNCA, rxode2, ubiquity, UnifiedDoseFinding, wnl, xpose, xpose.nlmixr2, xpose4.|